17:56 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida Mouse studies suggest inhibiting JNK1 could help treat Candida albicans infection. In a mouse model of C. albicans infection, knockout of JNK1 or two JNK1 inhibitor tool compounds decreased fungal burden and inflammation in...
17:40 , Nov 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Cell culture and mouse studies suggest inhibiting JNK1 or its substrate AP-1 could help treat the viral infection Japanese encephalitis (JE). In JE virus-infected human glioma and murine microglial cell lines, a JNK inhibitor...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase (JNK); JNK1 (MAPK8)

Dermatology INDICATION: Dermatitis Mouse studies suggest that inhibiting JNK could help treat atopic dermatitis. In a mouse model of atopic dermatitis, epidermal levels of JNK were higher than in normal mice. In cultured keratinocytes from the mouse...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase 2 (JNK2; MAPK9); JNK3 (MAPK10)

Neurology INDICATION: Neurology In vitro studies have identified aminopyrazole-based JNK2/3-selective inhibitors that could help treat neurodegenerative diseases linked to neuronal oxidative stress. In vitro, the lead compound inhibited JNK2, JNK3 and JNK1 at IC50 values of 836...
07:00 , Aug 18, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Diabetes; liver failure c-Jun N-terminal kinase (JNK) In vitro and mouse studies...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Marfan syndrome MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2); MAP kinase kinase...
07:00 , Apr 28, 2011 |  BC Innovations  |  Targets & Mechanisms

MAPping out aneurysm

A team from The Johns Hopkins University School of Medicine has uncovered a role for the MAP kinase pathway in aortic aneurysms caused by the genetic disorder Marfan syndrome. The findings could open up a...
08:00 , Jan 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) c-Jun N-terminal kinase 1 (JNK1; MAPK8) Studies in mice suggest that inhibiting JNK1...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

PregLem, Merck KGaA deal

Merck's Merck Serono S.A. unit granted PregLem exclusive, worldwide rights to develop and commercialize bentamapimod. Merck will receive an upfront payment and is eligible for milestones and royalties. PregLem said it plans to...
08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology c-Jun N-terminal kinase (JNK) Studies in cell culture and in rodents identified biaryl-substituted aminopyrimidine JNK inhibitors...